首页 | 本学科首页   官方微博 | 高级检索  
     

沙格列汀治疗血糖控制不佳2型糖尿病的临床观察
引用本文:夏彩霞,张广颖. 沙格列汀治疗血糖控制不佳2型糖尿病的临床观察[J]. 包头医学院学报, 2014, 0(3): 33-35
作者姓名:夏彩霞  张广颖
作者单位:夏彩霞 (廊坊市人民医院内分泌科,河北 廊坊,065000); 张广颖 (廊坊市人民医院内分泌科,河北 廊坊,065000);
摘    要:目的:观察沙格列汀治疗血糖控制不佳的2型糖尿病(Type 2 Diabetes Mellitus,T2DM)患者的临床有效性及安全性。方法:选取48例2型糖尿病患者,所有患者试验前均给予二甲双胍联合胰岛素治疗,但血糖控制不佳(HbA1c ﹥7.5%);将入选患者随机分为观察组(在原治疗基础上加用沙格列汀)和对照组(继续增加胰岛素剂量)各24例,治疗12周,观察并比较两组患者临床疗效的差异。结果:治疗12周后两组患者空腹血糖(fasting blood glucose, FPG)、餐后2小时血糖(2 hour postprandial blood glucose,2hPG)、糖化血红蛋白(glycosylated hemoglobin,HbA1c)均较治疗前下降( P ﹤0.05),组间比较差异无统计学意义( P ﹥0.05);与对照组比较,观察组患者胰岛素用量少( P ﹤0.05)、低血糖发生率降低( P ﹤0.05)、体重指数(body mass index,BMI)降低( P ﹤0.05)。结论:沙格列汀联合胰岛素治疗可以有效改善血糖控制,且无明显不良反应,具有较好的临床有效性和安全性。

关 键 词:沙格列汀  胰岛素  二甲双胍  2  型糖尿病

The Clinical Observation of Saxagliptin in the Treatment of Poor - controlled Type 2 Diabetes
XIA Caixia,ZHANG Guangying. The Clinical Observation of Saxagliptin in the Treatment of Poor - controlled Type 2 Diabetes[J]. Journal of Baotou Medical College, 2014, 0(3): 33-35
Authors:XIA Caixia  ZHANG Guangying
Affiliation:( Department of Endocrinology, Lanfang People's Hospital, Langfang 065000, China)
Abstract:Objective:To observe the clinical efficacy and safety of Saxagliptin in the treatment of poor - controlled type 2 diabetes(T2DM). Methods:48 patients with type 2 diabetes were randomly divided into the test group and the control group, with 24 cases in each group. Metformin and insulin were given to all patients from the both groups before the test,but with glyce-mia poorly controlled(HbA1C ﹥ 7. 5 % ). The test group was given saxagliptin,the control group was continually given increased doses of insulin. The clinical efficacy was observed and compared between the two groups 12 weeks after the treatment. Results:12 weeks after the treatment,the levels of fasting blood glucose(FPG),2 hour postprandial blood glucose(2hPG)and glycosy-lated hemoglobin(HbA1c)in the patients from the both groups were significantly lowered( P ﹤ 0. 05),but with no significant difference in them between groups( P ﹥ 0. 05). Compared with those in the control group,the patients in the test group took re-markably less insulin( P ﹤ 0. 05),with the incidence of hypoglycemia and body mass index(BMI)significantly reduced( P ﹤0. 05). Conclusion:Saxagliptin in combination with insulin can effectively control glycemia in the treatment of T2DM,without notable adverse effects,but with better clinical efficacy and safety.
Keywords:Saxagliptin  Insulin  Metformin  Type 2 Diabetes
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号